- Record: found
- Abstract: found
- Article: not found
Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Florence K Keane
1 ,
Ming-Hui Chen
2 ,
Danjie Zhang
2 ,
Brian J Moran
3 ,
Michelle H Braccioforte
3 ,
Anthony V D'Amico
4
Aug 15 2015
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Radiotherapy (RT), short-course androgen deprivation therapy (ADT), and brachytherapy in various combinations are treatment options for patients with intermediate-risk prostate cancer (PC), but the question of which combination if any is necessary to minimize PC-specific mortality (PCSM) risk in patients with favorable or unfavorable intermediate-risk PC is unknown. The authors assessed PCSM risk after commonly used treatments.